Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Capol Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled within 1 distinct art unit by 1 distinct examiner. The examiner assigned to this matter is PALENIK, JEFFREY T, who is the busiest examiner with 1 pending action. This represents a highly concentrated and singular point of prosecution for the company's current portfolio. With only 1 distinct examiner and 1 distinct art unit involved, the company's immediate patent strategy is focused on a single technical review.
The presence of 1 pending office action in a single art unit indicates a very specific focus for Capol Inc. at this time. Because the prosecution is limited to 1 distinct examiner, the outcome of the company's current patent efforts depends entirely on the interactions with PALENIK, JEFFREY T. This allows for a highly targeted approach to prosecution, as the practitioner only needs to navigate the specific requirements of one examiner. There is no complexity arising from multiple art units or varying examiner styles in this portfolio. The data shows a streamlined and singular path for the company's current biotechnology and pharmaceutical claims, with no other active matters currently complicating the prosecution landscape.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759542 | EXTRUSION-ENCAPSULATED CALCIUM SALTS AS OPACIFYING/WHITENING AGENTS | PALENIK, JEFFREY T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759542 | EXTRUSION-ENCAPSULATED CALCIUM SALTS AS OPACIFYING/WHITENING AGENTS | PALENIK, JEFFREY T | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18759542 | EXTRUSION-ENCAPSULATED CALCIUM SALTS AS OPACIFYING/WHITENING AGENTS | PALENIK, JEFFREY T | 1615 | §102§103§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCapol Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jeffrey T Palenik has the most, with 1 of Capol Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
